MALVERN, Pa., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Arun Upadhyay, Chief Scientific Officer, Head of Research & Development, will participate in an in-person fireside chat moderated by Daniil Gataulin, PhD, Senior Biotech Research Analyst, at Chardan's 8th Annual Genetic Medicines Conference being held Septembe ...

Jonathan Storey Source: Corporate Presentation. August 2024. Ocugen Inc. (NASDAQ:OCGN) is a clinical-stage biotechnology company developing gene and cell therapies using its proprietary platforms. They aim to restore retinal function in various ocular diseases. Since I last covered OCGN, the company has made promising strides targeting conditions such as retinitis pigmentosa [RP], goographic atrophy related to dry age-related macular degeneration [dAMD], Stargardt disease, and wet AMD. It also has an intrig ...

Core Insights - Ocugen, Inc. is participating in a workshop titled "U.S.-India Biotechnology Cooperation: Realizing Benefits, Reducing Risks" from September 9-11, 2024, in New Delhi, India, with Dr. Shankar Musunuri representing the company [1][2] - The workshop aims to explore opportunities for U.S.-India biotechnology collaboration, aligning with the initiative on Critical and Emerging Technology (iCET) [2] - Ocugen has established a site in Hyderabad, India, to enhance collaboration in the biotechnology sector [2] Company Overview - Ocugen, Inc. focuses on discovering, developing, and commercializing novel gene and cell therapies, and vaccines aimed at improving global health [3] - The company is advancing a breakthrough modifier gene therapy platform that has the potential to treat multiple retinal diseases with a single product [3] - Ocugen is also conducting research in infectious diseases and orthopedic diseases to address unmet medical needs [3]

Core Insights - Ocugen, Inc. is participating in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York, NY, where Dr. Shankar Musunuri will engage in a fireside chat [1][2] - The conference serves as a platform for Ocugen to showcase its recent corporate achievements and future milestones, with one-on-one meetings planned for investors [2] Event Details - The fireside chat is scheduled for September 9, 2024, at 1:30 p.m. ET, located at the Lotte New York Palace Hotel [3] - A live video webcast of the presentation will be available on Ocugen's investor site, with a replay archived for 90 days [3] Company Overview - Ocugen, Inc. focuses on discovering, developing, and commercializing novel gene and cell therapies, and vaccines aimed at improving global health [4] - The company is advancing a unique modifier gene therapy platform that has the potential to treat multiple retinal diseases with a single product, alongside research in infectious and orthopedic diseases [4]

MALVERN, Pa., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the third cohort of its Phase 1/2 GARDian clinical trial for OCU410ST (AAV-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease. Stargardt disease affects approximately 100,000 people in the United States (U.S.) an ...

Ocugen, Inc. (OCGN) announced that Health Canada has provided it a No Objection Letter to initiate the phase III liMeliGhT study evaluating its modifier gene therapy product candidate, OCU400, for treating retinitis pigmentosa (RP). Shares of OCGN were up 4.6% on Aug. 26 following the announcement of the news. Ocugen has already received clearance from the FDA to initiate a phase III study on OCU400 for the treatment of RP, a rare genetic disorder that can lead to vision loss and blindness. The FDA had prev ...

MALVERN, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Health Canada provided a "No Objection Letter" to initiate the OCU400 Phase 3 liMeliGhT (pronounced "limelight") clinical trial in Canada. OCU400 is a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP). "Expanding the clinical ...

Ocugen, Inc. (NASDAQ:OCGN) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Tiffany Hamilton - Head of Corporate Communications Shankar Musunuri - Chairman of the Board, CEO & Co-founder Michael Breininger - Corporate Controller Huma Qamar - Chief Medical Officer Conference Call Participants Sean Lee - H.C. Wainwright Robert LeBoyer - Noble Capital Markets Janani Sundararajan - Chardan Capital Markets Operator Good morning, and welcome to Ocugen's Second Quarter 2024 Financial ...

MALVERN, Pa., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it has received notification from FDA to begin its expanded access program (EAP) for the treatment of adult patients, aged 18 and older, with retinitis pigmentosa (RP) with OCU400—a modifier gene therapy product candidate. "Each clinical milestone achieved by OC ...

MALVERN, Pa., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it has received notification from FDA to begin its expanded access program (EAP) for the treatment of adult patients, aged 18 and older, with retinitis pigmentosa (RP) with OCU400—a modifier gene therapy product candidate. "Each clinical milestone achieved by OC ...